Liraglutide vs Exenatide

A detailed comparison to help you understand the differences and choose the right peptide for your research goals.

Liraglutide

Liraglutide is a GLP-1 receptor agonist FDA-approved as Victoza for type 2 diabetes and Saxenda for chronic weight management. It was one of the first daily GLP-1 agonists and paved the way for newer weekly options like semaglutide.

Full details →

Exenatide

Exenatide was the first GLP-1 receptor agonist approved in the US, derived from a compound found in Gila monster saliva. Available as Byetta (twice daily) and Bydureon (once weekly extended-release).

Full details →

Side-by-Side Comparison

AspectLiraglutideExenatide
MechanismBinds to and activates GLP-1 receptors, stimulating insulin secretion in a glucose-dependent manner, suppressing glucagon release, slowing gastric emptying, and reducing appetite through central nervous system effects.Synthetic version of exendin-4, which activates GLP-1 receptors to enhance glucose-dependent insulin secretion, suppress glucagon, slow gastric emptying, and promote satiety.
Typical DosageSaxenda (weight loss): Start 0.6mg daily, increase weekly by 0.6mg to maintenance dose of 3mg daily. Victoza (diabetes): 0.6mg to 1.8mg daily.Byetta: 5mcg twice daily for 1 month, then 10mcg twice daily. Bydureon: 2mg subcutaneously once weekly.
AdministrationSubcutaneous injection once daily at any time, independent of meals. Rotate injection sites. Can be used with oral diabetes medications.Byetta: Inject within 60 minutes before morning and evening meals. Bydureon: Any time of day, with or without meals. Do not mix with insulin in same syringe.
Side EffectsNausea, vomiting, diarrhea, constipation, headache, decreased appetite. GI effects typically diminish over time with continued use.Nausea (especially initially), vomiting, diarrhea, dizziness, headache, and injection site reactions (particularly with Bydureon).
Best For

What They Have in Common

Both Liraglutide and Exenatide are commonly used for:

Ready to Learn More?